As of January 22, 2025, C4 Therapeutics (CCCC) has a market cap of $0.26 billion USD. According to our data, C4 Therapeutics is ranked No.6838 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.26 B |
3.06%
|
Dec 31, 2024 | $0.25 B |
-36.28%
|
Dec 29, 2023 | $0.40 B |
-4.24%
|
Dec 30, 2022 | $0.42 B |
-81.68%
|
Dec 31, 2021 | $2.27 B |
-2.81%
|
Dec 31, 2020 | $2.34 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Arvinas
ARVN
|
$1.25 B |
0.000 M
|
USA
|
Nurix Therapeutics
NRIX
|
$1.39 B |
0.000 M
|
USA
|
Kymera Therapeutics
KYMR
|
$2.86 B |
0.000 M
|
USA
|
Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Bristol-Myers Squibb
BMY
|
$115.79 B |
-0.003 M
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Pfizer
PFE
|
$147.40 B |
-0.003 M
|
USA
|
Merck
MRK
|
$242.04 B |
-0.000 M
|
USA
|
Eli Lilly
LLY
|
$678.07 B |
0.022 M
|
USA
|
Sanofi
SNY
|
$129.14 B |
0.001 M
|
France
|
Novartis
NVS
|
$196.27 B |
-0.007 M
|
Switzerland
|
AstraZeneca
AZN
|
$211.49 B |
0.007 M
|
UK
|
Market Cap | = | CCCC Stock Price | * | CCCC Shares Outstanding |
= | $3.71 | * | 70.59 M | |
= | $0.26 B |